Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System

Heart Failure Clinical Trial

— Yale-HF  

Official title:

Retrospective and Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System Via a Live Registry

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04237701
• Other study ID #: 2000026771
• Secondary ID: No NIH funding
• Status: Recruiting
• Start date: October 1, 2019
• Est. completion date: December 30, 2025

Study information

• Verified date: January 2024
• Source: Yale University
• Contact: Tariq Ahmad, MD MPH
• Phone: (203) 843-1667
• Email: Tariq.ahmad[@]yale.edu
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The Yale HF Registry is a live EHR based registry that allows for retrospective and real-time monitoring of Heart Failure case across the Yale New Haven Health System.

Description:

Electronic Health Records based registries can be an important resource for precision medicine delivery by understanding the population burden of chronic diseases such as heart failure. These registries can allow for a deeper understanding of gaps in guideline recommended therapies among patients who are under the purview of large, integrated Therefore, we have created a live registry within the integrated Yale New Haven Health System-the Yale Heart Failure Registry-that includes all patients with a diagnosis of HF and has detailed information about demographics, comorbidities, laboratories, imaging, medications, and clinical outcomes (including hospital readmissions). The registry is updated daily and can be queried for clinically relevant questions aimed at quality improvement.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40000
• Est. completion date: December 30, 2025
• Est. primary completion date: December 30, 2025
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Seen within the Yale New Haven Health System
• Diagnosis of heart failure

Exclusion Criteria:

• Age<18

Related Conditions & MeSH terms

• Heart Failure
• Heart Failure NYHA Class IV
• Heart Failure With Preserved Ejection Fraction
• Heart Failure With Reduced Ejection Fraction

Locations

Country	Name	City	State
United States	Yale New Haven Health System	New Haven	Connecticut

Sponsors (1)

Lead Sponsor	Collaborator
Yale University

Country where clinical trial is conducted

United States, 

References & Publications (1)

Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, Duffy CI, Hill CL, McCague K, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, Butler J. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. J — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants hospitalized for heart failure	Heart Failure hospitalizations	10 years
Primary	Doses of therapies that comprise guideline directed medical therapy	Appropriate use of guideline recommended therapies. This will include doses of beta blockers, ACE inhibitors, ARBs, ARNI, SGLT2i, ICD use.	10 years